Can a common supplement stop severe COVID? early trial tests MitoQ
NCT ID NCT05381454
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether the dietary supplement MitoQ could prevent severe viral infections, like COVID-19, in adults who had close contact with a sick person. Eighty asymptomatic adults were given MitoQ or no treatment and monitored for illness. The goal was to see if the supplement reduces infection rates and symptom severity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mitoquinone/mitoquinol mesylate (MitoQ)
What this could lead to
If it works, this could point toward a simple supplement to prevent severe viral illness after exposure.
What could go wrong
This is an early, small study (80 people) with no blinding, so results may not be reliable or generalizable. The supplement may not prevent illness or reduce severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75219, United States